Search > Results
You searched for: EV200117 (EV-TRACK ID)
Showing 1 - 6 of 6
Showing 1 - 6 of 6
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV200117 | 2/6 | Homo sapiens | HEK |
(d)(U)C UF qEV |
Cocozza, Federico | 2020 | 50% | |
Study summaryFull title
All authors
Federico Cocozza, Nathalie Névo, Ester Piovesana, Xavier Lahaye, Julian Buchrieser, Olivier Schwartz, Nicolas Manel, Mercedes Tkach, Clotilde Théry, Lorena Martin‐Jaular
Journal
J Extracell Vesicles
Abstract
SARS‐CoV‐2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 an (show more...)
EV-METRIC
50% (87th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
HEK MOCK
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Ultrafiltration Commercial method Protein markers
EV: CD81/ ACE2/ ADAM10/ CD63/ syntenin-1/ HSP70
non-EV: AChe Proteomics
no
Show all info
Study aim
Function/New methodological development
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
HEK
EV-harvesting Medium
EV-depleted medium
Preparation of EDS
overnight (16h) at >=100,000g
Cell viability (%)
89
Cell count
3.5E7-8.5E7
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Pelleting performed
No
Ultra filtration
Cut-off size (kDa)
10
Membrane type
Regenerated cellulose
Commercial kit
qEV
Characterization: Protein analysis
Protein Concentration Method
microBCA
Western Blot
Antibody details provided?
Yes
Antibody dilution provided?
Yes
Lysis buffer provided?
Yes
Detected EV-associated proteins
CD63/ syntenin-1/ ACE2/ ADAM10/ CD81/ HSP70
Not detected contaminants
AChe
ELISA
Antibody details provided?
No
Detected EV-associated proteins
ACE2
Flow cytometry
Antibody details provided?
No
Detected EV-associated proteins
CD63/ CD81/ syntenin-1
Detected EV-associated proteins
CD81/ CD63/ syntenin-1
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Median
Reported size (nm)
141.8
EV concentration
Yes
Particle yield
Yes, as number of particles per million cells 5.00E+08
|
||||||||
EV200117 | 3/6 | Homo sapiens | HEK |
(d)(U)C UF qEV |
Cocozza, Federico | 2020 | 50% | |
Study summaryFull title
All authors
Federico Cocozza, Nathalie Névo, Ester Piovesana, Xavier Lahaye, Julian Buchrieser, Olivier Schwartz, Nicolas Manel, Mercedes Tkach, Clotilde Théry, Lorena Martin‐Jaular
Journal
J Extracell Vesicles
Abstract
SARS‐CoV‐2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 an (show more...)
EV-METRIC
50% (87th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
HEK ACE2
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Ultrafiltration Commercial method Protein markers
EV: CD81/ ACE2/ ADAM10/ CD63/ syntenin-1/ HSP70
non-EV: AChe Proteomics
no
Show all info
Study aim
Function/New methodological development
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
HEK
EV-harvesting Medium
EV-depleted medium
Preparation of EDS
overnight (16h) at >=100,000g
Cell viability (%)
89
Cell count
3.5E7-8.5E7
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Pelleting performed
No
Ultra filtration
Cut-off size (kDa)
10
Membrane type
Regenerated cellulose
Commercial kit
qEV
Characterization: Protein analysis
Protein Concentration Method
microBCA
Western Blot
Antibody details provided?
Yes
Antibody dilution provided?
Yes
Lysis buffer provided?
Yes
Detected EV-associated proteins
CD63/ syntenin-1/ ACE2/ ADAM10/ CD81/ HSP70
Not detected contaminants
AChe
ELISA
Antibody details provided?
No
Detected EV-associated proteins
ACE2
Flow cytometry
Antibody details provided?
No
Detected EV-associated proteins
CD63/ CD81/ syntenin-1
Detected EV-associated proteins
CD81/ CD63/ syntenin-1
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Median
Reported size (nm)
145.5
EV concentration
Yes
Particle yield
Yes, as number of particles per million cells 7.00E+08
|
||||||||
EV200117 | 4/6 | Homo sapiens | HEK |
(d)(U)C UF qEV |
Cocozza, Federico | 2020 | 50% | |
Study summaryFull title
All authors
Federico Cocozza, Nathalie Névo, Ester Piovesana, Xavier Lahaye, Julian Buchrieser, Olivier Schwartz, Nicolas Manel, Mercedes Tkach, Clotilde Théry, Lorena Martin‐Jaular
Journal
J Extracell Vesicles
Abstract
SARS‐CoV‐2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 an (show more...)
EV-METRIC
50% (87th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
HEK ACE2 and TMPRSS2
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Ultrafiltration Commercial method Protein markers
EV: CD81/ ACE2/ ADAM10/ CD63/ syntenin-1/ HSP70
non-EV: AChe Proteomics
no
Show all info
Study aim
Function/New methodological development
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
HEK
EV-harvesting Medium
EV-depleted medium
Preparation of EDS
overnight (16h) at >=100,000g
Cell viability (%)
89
Cell count
3.5E7-8.5E7
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Pelleting performed
No
Ultra filtration
Cut-off size (kDa)
10
Membrane type
Regenerated cellulose
Commercial kit
qEV
Characterization: Protein analysis
Protein Concentration Method
microBCA
Western Blot
Antibody details provided?
Yes
Antibody dilution provided?
Yes
Lysis buffer provided?
Yes
Detected EV-associated proteins
syntenin-1/ ACE2/ ADAM10/ CD63/ CD81/ HSP70
Not detected contaminants
AChe
ELISA
Antibody details provided?
No
Detected EV-associated proteins
ACE2
Flow cytometry
Antibody details provided?
No
Detected EV-associated proteins
CD63/ CD81/ syntenin-1
Detected EV-associated proteins
CD81/ CD63/ syntenin-1
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Median
Reported size (nm)
153.9
EV concentration
Yes
Particle yield
Yes, as number of particles per million cells 6.00E+08
|
||||||||
EV200117 | 1/6 | Homo sapiens | HEK |
(d)(U)C UF qEV |
Cocozza, Federico | 2020 | 38% | |
Study summaryFull title
All authors
Federico Cocozza, Nathalie Névo, Ester Piovesana, Xavier Lahaye, Julian Buchrieser, Olivier Schwartz, Nicolas Manel, Mercedes Tkach, Clotilde Théry, Lorena Martin‐Jaular
Journal
J Extracell Vesicles
Abstract
SARS‐CoV‐2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 an (show more...)
EV-METRIC
38% (80th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Ultrafiltration Commercial method Protein markers
EV: CD63/ CD81/ Adam10/ Ace2/ ACE2/ syntenin-1
non-EV: None Proteomics
no
Show all info
Study aim
Function/New methodological development
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
HEK
EV-harvesting Medium
EV-depleted medium
Preparation of EDS
overnight (16h) at >=100,000g
Cell viability (%)
89
Cell count
3.5E7-8.5E7
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Pelleting performed
No
Ultra filtration
Cut-off size (kDa)
10
Membrane type
Regenerated cellulose
Commercial kit
qEV
Characterization: Protein analysis
Protein Concentration Method
microBCA
Western Blot
Antibody details provided?
Yes
Antibody dilution provided?
Yes
Lysis buffer provided?
Yes
Detected EV-associated proteins
CD63/ syntenin-1/ Ace2/ Adam10/ CD81
ELISA
Antibody details provided?
No
Detected EV-associated proteins
ACE2
Flow cytometry
Antibody details provided?
No
Detected EV-associated proteins
CD63
Detected EV-associated proteins
CD63/ syntenin-1/ CD81
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Median
Reported size (nm)
102.9
EV concentration
Yes
Particle yield
Yes, as number of particles per million cells 4.70E+07
|
||||||||
EV200117 | 5/6 | Homo sapiens | Caco-2 |
(d)(U)C UF qEV |
Cocozza, Federico | 2020 | 38% | |
Study summaryFull title
All authors
Federico Cocozza, Nathalie Névo, Ester Piovesana, Xavier Lahaye, Julian Buchrieser, Olivier Schwartz, Nicolas Manel, Mercedes Tkach, Clotilde Théry, Lorena Martin‐Jaular
Journal
J Extracell Vesicles
Abstract
SARS‐CoV‐2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 an (show more...)
EV-METRIC
38% (80th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Ultrafiltration Commercial method Protein markers
EV: CD81/ ACE2/ ADAM10/ CD63/ syntenin-1
non-EV: None Proteomics
no
Show all info
Study aim
Function/New methodological development
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
Caco-2
EV-harvesting Medium
Serum free medium
Cell viability (%)
98
Cell count
6.00E+07
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Pelleting performed
No
Ultra filtration
Cut-off size (kDa)
10
Membrane type
Regenerated cellulose
Commercial kit
qEV
Characterization: Protein analysis
Protein Concentration Method
microBCA
Western Blot
Antibody details provided?
Yes
Antibody dilution provided?
Yes
Lysis buffer provided?
Yes
Detected EV-associated proteins
syntenin-1/ ACE2/ ADAM10/ CD63/ CD81
ELISA
Antibody details provided?
No
Detected EV-associated proteins
ACE2
Flow cytometry
Antibody details provided?
No
Detected EV-associated proteins
CD63/ CD81/ syntenin-1
Detected EV-associated proteins
CD81/ CD63/ syntenin-1
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Median
Reported size (nm)
172.3
EV concentration
Yes
Particle yield
Yes, as number of particles per million cells 3.00E+08
|
||||||||
EV200117 | 6/6 | Homo sapiens | Calu-3 |
(d)(U)C UF qEV |
Cocozza, Federico | 2020 | 38% | |
Study summaryFull title
All authors
Federico Cocozza, Nathalie Névo, Ester Piovesana, Xavier Lahaye, Julian Buchrieser, Olivier Schwartz, Nicolas Manel, Mercedes Tkach, Clotilde Théry, Lorena Martin‐Jaular
Journal
J Extracell Vesicles
Abstract
SARS‐CoV‐2 entry is mediated by binding of the spike protein (S) to the surface receptor ACE2 an (show more...)
EV-METRIC
38% (80th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(Differential) (ultra)centrifugation
Ultrafiltration Commercial method Protein markers
EV: CD81/ ACE2/ ADAM10/ CD63/ syntenin-1
non-EV: None Proteomics
no
Show all info
Study aim
Function/New methodological development
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
Calu-3
EV-harvesting Medium
Serum free medium
Cell viability (%)
91
Cell count
6.50E+06
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Below or equal to 800 g
Between 800 g and 10,000 g Pelleting performed
No
Ultra filtration
Cut-off size (kDa)
10
Membrane type
Regenerated cellulose
Commercial kit
qEV
Characterization: Protein analysis
Protein Concentration Method
microBCA
Western Blot
Antibody details provided?
Yes
Antibody dilution provided?
Yes
Lysis buffer provided?
Yes
Detected EV-associated proteins
syntenin-1/ ACE2/ ADAM10/ CD63/ CD81
ELISA
Antibody details provided?
No
Detected EV-associated proteins
ACE2
Flow cytometry
Antibody details provided?
No
Detected EV-associated proteins
CD63/ CD81/ syntenin-1
Detected EV-associated proteins
CD81/ syntenin-1/ CD63
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Median
Reported size (nm)
174.8
EV concentration
Yes
Particle yield
Yes, as number of particles per million cells 1.00E+09
|
||||||||
1 - 6 of 6 |
EV-TRACK ID | EV200117 | |||||
---|---|---|---|---|---|---|
species | Homo sapiens | |||||
sample type | Cell culture | |||||
cell type | HEK | HEK | HEK | HEK | Caco-2 | Calu-3 |
medium | EV-depleted medium | EV-depleted medium | EV-depleted medium | EV-depleted medium | Serum free medium | Serum free medium |
condition | HEK MOCK | HEK ACE2 | HEK ACE2 and TMPRSS2 | Control condition | Control condition | Control condition |
separation protocol | dUC Ultrafiltration qEV | dUC Ultrafiltration qEV | dUC Ultrafiltration qEV | dUC Ultrafiltration qEV | dUC Ultrafiltration qEV | dUC Ultrafiltration qEV |
Exp. nr. | 2 | 3 | 4 | 1 | 5 | 6 |
EV-METRIC % | 50 | 50 | 50 | 38 | 38 | 38 |